Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Novel C-2 Aromatic Heterocycle-Substituted Triterpenoids Inhibit Hedgehog Signaling in GLI1 Overexpression Cancer Cells

I. Frydrych, B. Choma, L. Slavíková, J. Pokorný, N. Jakubcová, S. Ludha, S. Gurská, J. Řehulka, B. Lišková, P. Džubák, M. Hajdúch, M. Urban

. 2025 ; 10 (10) : 10617-10632. [pub] 20250304

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008209

The hedgehog signaling pathway plays an important role in vertebrate embryonic development, tissue homeostasis, and tumorigenesis. Constitutive activation of Hh signaling in various human tumors leads to GLI-mediated transcription and tumor progression. Based on the preliminary screening of a large library of known triterpenes that exhibited interesting Hh inhibitory activity, we designed and synthesized a new series of triterpenoid analogues containing aromatic heterocyclic substituents at position C-2 to enhance their interference with Hh signaling. In this study, we evaluated the effect of 15 synthesized triterpenoids on cell proliferation and Hh pathway activity in relevant cancer cell lines. Among these compounds, two derivatives, 11a and 11b, both featuring a furan ring at position C-2, demonstrated potent inhibitory effects on proliferation and induced cell death in nonsmall cell lung cancer (NSCLC) and prostate cancer cell lines exhibiting hyper-activated Hh signaling. Moreover, these compounds significantly reduced GLI-mediated transcription in cell-based reporter assays. Detailed immunoblot analyses revealed that compounds 11a and 11b decreased the expression of endogenous GLI1 protein and its target genes associated with tumor progression and proliferation, such as Cyclin D1, N-Myc, and Bcl-2, in A549 and DU-145 cancer cells. These findings suggest that the antiproliferative effects of 11a and 11b are mediated through inhibition of the Hh signaling pathway and are promising candidates for the development of new anticancer therapies targeting Hh-dependent tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008209
003      
CZ-PrNML
005      
20250422095758.0
007      
ta
008      
250408s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acsomega.4c11479 $2 doi
035    __
$a (PubMed)40124057
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Frydrych, Ivo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $1 https://orcid.org/0000000314121607 $7 xx0169396
245    10
$a Novel C-2 Aromatic Heterocycle-Substituted Triterpenoids Inhibit Hedgehog Signaling in GLI1 Overexpression Cancer Cells / $c I. Frydrych, B. Choma, L. Slavíková, J. Pokorný, N. Jakubcová, S. Ludha, S. Gurská, J. Řehulka, B. Lišková, P. Džubák, M. Hajdúch, M. Urban
520    9_
$a The hedgehog signaling pathway plays an important role in vertebrate embryonic development, tissue homeostasis, and tumorigenesis. Constitutive activation of Hh signaling in various human tumors leads to GLI-mediated transcription and tumor progression. Based on the preliminary screening of a large library of known triterpenes that exhibited interesting Hh inhibitory activity, we designed and synthesized a new series of triterpenoid analogues containing aromatic heterocyclic substituents at position C-2 to enhance their interference with Hh signaling. In this study, we evaluated the effect of 15 synthesized triterpenoids on cell proliferation and Hh pathway activity in relevant cancer cell lines. Among these compounds, two derivatives, 11a and 11b, both featuring a furan ring at position C-2, demonstrated potent inhibitory effects on proliferation and induced cell death in nonsmall cell lung cancer (NSCLC) and prostate cancer cell lines exhibiting hyper-activated Hh signaling. Moreover, these compounds significantly reduced GLI-mediated transcription in cell-based reporter assays. Detailed immunoblot analyses revealed that compounds 11a and 11b decreased the expression of endogenous GLI1 protein and its target genes associated with tumor progression and proliferation, such as Cyclin D1, N-Myc, and Bcl-2, in A549 and DU-145 cancer cells. These findings suggest that the antiproliferative effects of 11a and 11b are mediated through inhibition of the Hh signaling pathway and are promising candidates for the development of new anticancer therapies targeting Hh-dependent tumors.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Choma, Barbora $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic
700    1_
$a Slavíková, Lucie $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic
700    1_
$a Pokorný, Jan $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic $u Laboratory of Medicinal and Organic Chemistry, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
700    1_
$a Jakubcová, Nikola $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic $u Laboratory of Medicinal and Organic Chemistry, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
700    1_
$a Ludha, Sandra $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic
700    1_
$a Gurská, Soňa $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
700    1_
$a Řehulka, Jiří $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
700    1_
$a Lišková, Barbora $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
700    1_
$a Džubák, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Czech Advanced Technology and Research Institute, Palacký University Olomouc, Šlechtitelů 241/27, Olomouc-Holice 783 71, Czech Republic
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Czech Advanced Technology and Research Institute, Palacký University Olomouc, Šlechtitelů 241/27, Olomouc-Holice 783 71, Czech Republic
700    1_
$a Urban, Milan $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic $u Laboratory of Medicinal and Organic Chemistry, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $1 https://orcid.org/000000028249028X $7 xx0117688
773    0_
$w MED00207589 $t ACS omega $x 2470-1343 $g Roč. 10, č. 10 (2025), s. 10617-10632
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40124057 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095759 $b ABA008
999    __
$a ok $b bmc $g 2306304 $s 1245284
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 10 $c 10 $d 10617-10632 $e 20250304 $i 2470-1343 $m ACS omega $n ACS Omega $x MED00207589
LZP    __
$a Pubmed-20250408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...